Series B - Second Genome
Investment Firm
Overview
Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.
Announced Date
Apr 13, 2016
Closed on Date
Apr 13, 2016
Funding Type
Series B
Highlights
Location
United States, North America
Social
Investor Lead
Roche Venture Fund
Roche Venture Fund is a early_stage_venture and late_stage_venture firm.
SR One
SR One is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Pfizer Venture Investments
Pfizer Venture Investments is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Participant Investors
12
Round Details and Background
Second Genome raised $51000000 on 2016-04-13 in Series B
Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.
Company Funding History
4
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Oct 03, 2017 |  Grant - Second Genome | - | undefined | |
| Apr 13, 2016 | Series B - Second Genome | 12 | - | 51.0M |
| Aug 09, 2011 | Series A - Second Genome | - | 5.0M | |
| Jun 05, 2013 | Series A - Second Genome | 3 | - | 6.5M |
Recent Activity
There is no recent news or activity for this profile.